BioBreakthroughs

Join us on the latest episode! Our Guest: Simon Allen, Former CEO, Anebulo Pharmaceuticals

What you'll get out of this episode:
  • Journey from biochemistry to sell-side biotech business development.
  • Current treatment landscape for ACI and the limitations therein.
  • Introduction to ANEB-001, a promising antidote aimed at the CB1 receptor to counter cannabinoid overload.
  • Impact of synthetic cannabinoids and the silent peril they pose.
  • Upcoming milestones: Finalization of Phase 2 data and optimistic outlook towards FDA outcomes.
*Since the recording of this episode Simon has moved onto new endeavors*

To learn more about Anebulo Pharmaceuticals: https://www.anebulo.com/

Our sponsors for this episode are:
Sage Growth Partners https://sage-growth.com/

What is BioBreakthroughs?

Welcome to BioBreakthroughs, the podcast that delves deep into the world of biotech and pharmaceuticals to bring you the latest and most exciting advancements in the field. Join us as we explore groundbreaking discoveries, cutting-edge research, and game-changing innovations that are shaping the future of healthcare. Produced by Slice of Healthcare.